Sharecast News
30 Jun, 2020 16:22

Immunodiagnostic Systems starts sale of Covid antibody test

ep vecinos del municipio madrileno de torrejon se realizan una de las pruebas diagnosticas de
Vecinos del municipio madrileño de Torrejón se realizan una de las pruebas diagnósticas de Covid-19Ricardo Rubio - Europa Press

Laboratory diagnostic services provider Immunodiagnostic Systems announced on Tuesday that its “fully automated” SARS-CoV-2 (Covid-19) IgG antibody test was available for sale.

The AIM-traded firm said the test could now be purchased by customers in the UK, the European Union, and a number of other countries which accept the CE-mark as the basis of regulatory approval.

It said it had started the process of working with a number of national reference centers and governmental bodies, to ensure a roll-out according to national guidelines.

“We are pleased to announce the release to the market of our automated SARS -CoV-2 antibody test, running on the IDS-iSYS analyser,” said chief executive officer Jaap Stuut.

“Immunodiagnostic Systems will now seek to commercialise this test via our direct sales force in Europe, and through our extensive distribution network elsewhere, and we look forward to joining the efforts to minimise the impact of the Covid-19 virus.”

At 1534 BST, shares in Immunodiagnostic Systems were up 10% at 264p.

News Source: © 2020 Web Financial Group (UK) Limited. All rights reserved. Terms of use and legal notice

Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.

 

Important Legal Notice about News Sources

 

Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author.

We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.